ATE490244T1 - Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren - Google Patents

Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren

Info

Publication number
ATE490244T1
ATE490244T1 AT04704951T AT04704951T ATE490244T1 AT E490244 T1 ATE490244 T1 AT E490244T1 AT 04704951 T AT04704951 T AT 04704951T AT 04704951 T AT04704951 T AT 04704951T AT E490244 T1 ATE490244 T1 AT E490244T1
Authority
AT
Austria
Prior art keywords
compounds
methods
compositions containing
substituted pyrazoles
pyrazoles
Prior art date
Application number
AT04704951T
Other languages
German (de)
English (en)
Inventor
Emma Parmee
Subharekha Raghavan
Teresa Beeson
Dong-Ming Shen
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32850762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE490244(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE490244T1 publication Critical patent/ATE490244T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04704951T 2003-01-27 2004-01-23 Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren ATE490244T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44282803P 2003-01-27 2003-01-27
PCT/US2004/001927 WO2004069158A2 (en) 2003-01-27 2004-01-23 Substituted pyrazoles, compositions containing such compounds and methods of use

Publications (1)

Publication Number Publication Date
ATE490244T1 true ATE490244T1 (de) 2010-12-15

Family

ID=32850762

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04704951T ATE490244T1 (de) 2003-01-27 2004-01-23 Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren

Country Status (8)

Country Link
US (2) US7572922B2 (enExample)
EP (1) EP1590336B1 (enExample)
JP (2) JP4560035B2 (enExample)
AT (1) ATE490244T1 (enExample)
AU (2) AU2004210127B2 (enExample)
CA (1) CA2513102C (enExample)
DE (1) DE602004030318D1 (enExample)
WO (1) WO2004069158A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2513102C (en) 2003-01-27 2011-03-22 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
CN101333192A (zh) 2003-04-03 2008-12-31 默克公司 作为钠通道阻滞剂的联芳基取代吡唑
SI1756064T1 (sl) 2004-06-04 2008-12-31 Merck & Co Inc Derivati pirazola, sestavki vsebujoäśi takĺ ne sestavine in postopki uporabe
US7649009B2 (en) 2004-07-07 2010-01-19 Merck & Co., Inc. Pyrazole amide derivatives, compositions containing such compounds and methods of use
ATE468853T1 (de) * 2004-07-22 2010-06-15 Merck Sharp & Dohme Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US8569352B2 (en) 2005-06-27 2013-10-29 Exelixis Patent Company Llc Imidazole based LXR modulators
US7709658B2 (en) * 2005-07-26 2010-05-04 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
WO2007111864A2 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN101415683B (zh) 2006-03-31 2013-07-17 诺瓦提斯公司 新化合物
WO2007136577A2 (en) 2006-05-16 2007-11-29 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
EP2786985B1 (en) 2007-02-09 2018-11-28 Metabasis Therapeutics, Inc. Antagonists of the glucagon receptor
EP2178858B1 (en) * 2007-08-02 2011-12-28 Recordati Ireland Limited Novel heterocyclic compounds as mglu5 antagonists
WO2009035558A1 (en) * 2007-09-12 2009-03-19 Merck & Co., Inc. Process for the production of a crystalline glucagon receptor antagonist compound
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
EP2210876B1 (en) 2007-11-01 2015-05-20 Takeda Pharmaceutical Company Limited Heterocyclic compound as glucagon antagonist
NZ586190A (en) 2007-12-26 2013-05-31 Elster Electricity Llc A utility meter network wherein meters can transmit electrical and other readings to a collector by using other meters as repeaters
US8436043B2 (en) 2008-03-05 2013-05-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2009140342A1 (en) * 2008-05-16 2009-11-19 Schering Corporation Glucagon receptor antagonists, compositions, and methods for their use
WO2010007943A1 (ja) * 2008-07-17 2010-01-21 旭化成ファーマ株式会社 含窒素複素環化合物
CN104803891B (zh) 2008-08-13 2017-10-20 症变治疗公司 胰高血糖素拮抗剂
WO2010030722A1 (en) * 2008-09-15 2010-03-18 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AR073412A1 (es) * 2008-10-03 2010-11-03 Schering Corp Derivados de espiro imidazolona como antagonistas del receptor glucagon y composiciones que los comprende.
EP2344467A1 (en) * 2008-10-10 2011-07-20 Lonza Ltd. Process for preparing 2-alkyl-3-aroyl-5-nitro-benzofurans
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010144664A1 (en) * 2009-06-12 2010-12-16 Schering Corporation Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
US8735604B2 (en) 2009-09-22 2014-05-27 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
CN107021951B (zh) * 2010-06-30 2020-10-20 赛克里翁治疗有限公司 sGC刺激物
CN103402515B (zh) 2010-11-09 2017-05-17 铁木医药有限公司 sGC刺激剂
RU2013127611A (ru) 2010-12-23 2015-01-27 Пфайзер Инк. Модуляторы глюкагонового рецептора
MX2013009140A (es) 2011-02-08 2013-10-01 Pfizer Moduladores del receptor de glucagon.
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
TWI757332B (zh) * 2016-09-06 2022-03-11 比利時商健生藥品公司 使用作為升糖素受體拮抗劑之吲唑衍生物
TW201811752A (zh) * 2016-09-06 2018-04-01 比利時商健生藥品公司 用作升糖素受體拮抗劑之吲唑衍生物
TW202003453A (zh) 2018-02-13 2020-01-16 美商利根德製藥公司 升糖素受體拮抗劑
CA3243048A1 (en) * 2021-12-23 2025-04-08 Vib Vzw 2-PYRAZOLE, ANILINES AND RELATED ANALOGUES TO INHIBIT YAP/TAZ-TEAD
WO2025034531A1 (en) * 2023-08-04 2025-02-13 The University Of Vermont And State Agricultural College Small molecule allosteric modulator to pac1 receptor and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
BE1009189A3 (fr) * 1995-03-14 1996-12-03 Solvay Procede pour la fabrication d'un corps creux.
AU702887B2 (en) 1995-10-31 1999-03-11 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
JP2001504489A (ja) 1996-11-20 2001-04-03 メルク エンド カンパニー インコーポレーテッド トリアリール置換イミダゾール及び使用方法
EP0959886A4 (en) 1996-11-20 2001-05-02 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS
WO1998021957A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
CA2274592C (en) 1996-12-12 2007-03-13 Banyu Pharmaceutical Co., Ltd. Pyrazole derivatives
GEP20022812B (en) 1997-04-18 2002-10-25 Searle & Co Using Cyclooxygenase-2 Inhibitors for Preparing Medicinal Means to Prevent Cardiovascular Disorders Connected with Inflammation Processes and Pharmaceutical Compositions Containing These Inhibitors
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP1024134A4 (en) 1997-10-09 2003-05-14 Ono Pharmaceutical Co DERIVATIVES OF AMINOBUTANIC ACID
CN1284945A (zh) 1997-12-19 2001-02-21 安姆根有限公司 取代的吡啶和哒嗪化合物及其药物用途
IL141786A0 (en) 1998-09-17 2002-03-10 Bristol Myers Squibb Co A pharmaceutical composition for treating diabetes containing an ap2 inhibitor
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
PL352367A1 (en) 1999-05-17 2003-08-25 Novo Nordisk As Glucagon antagonists/inverse agonists
JP2003506443A (ja) 1999-08-10 2003-02-18 バイエルクロップサイエンス株式会社 除草性テトラゾリノン誘導体
DK1228067T3 (da) * 1999-11-10 2004-12-06 Takeda Chemical Industries Ltd 5-leddede heterocykliske forbindelser med hypoglykæmisk og hypolipidæmisk virkning
AU2001265834A1 (en) 2000-06-23 2002-01-08 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
WO2002040444A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
EP1463715A1 (en) 2001-12-03 2004-10-06 Novo Nordisk A/S Novel glucagon antagonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
AU2002351730A1 (en) 2001-12-19 2003-06-30 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
KR100926839B1 (ko) 2002-02-01 2009-11-12 다이닛본 스미토모 세이야꾸 가부시끼가이샤 ２－퓨란 카르복시산 하이드라지드 화합물 및 그것을함유하는 의약 조성물
AU2003233780A1 (en) 2002-06-27 2004-01-19 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
MXPA05000816A (es) 2002-07-19 2005-04-28 Baxter Int Sistemas y metodos para realizar dialisis peritoneal.
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
US20060116366A1 (en) 2002-12-04 2006-06-01 Parmee Emma R Spirocyclic ureas, compositions containing such compounds and methods of use
CA2513102C (en) 2003-01-27 2011-03-22 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
EA200501607A1 (ru) 2003-04-14 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Замещённые фенилалкановые кислоты
DE10317108A1 (de) 2003-04-14 2004-11-11 Mutzbauer, Till S., Dr. Dr.med. Transdermal applizierbares Beruhigungs- und Sedierungsmittel
JP2006528687A (ja) 2003-05-09 2006-12-21 メルク　エンド　カムパニー　インコーポレーテッド ベンズイミダゾール、こうした化合物を含有する組成物および使用方法
SI1756064T1 (sl) 2004-06-04 2008-12-31 Merck & Co Inc Derivati pirazola, sestavki vsebujoäśi takĺ ne sestavine in postopki uporabe
ATE468853T1 (de) * 2004-07-22 2010-06-15 Merck Sharp & Dohme Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
AR056574A1 (es) 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Also Published As

Publication number Publication date
AU2009240856A1 (en) 2009-12-17
US20060084681A1 (en) 2006-04-20
JP2010150267A (ja) 2010-07-08
AU2004210127A1 (en) 2004-08-19
DE602004030318D1 (de) 2011-01-13
CA2513102A1 (en) 2004-08-19
JP4560035B2 (ja) 2010-10-13
WO2004069158A2 (en) 2004-08-19
EP1590336A2 (en) 2005-11-02
EP1590336A4 (en) 2008-12-17
WO2004069158A3 (en) 2005-01-20
EP1590336B1 (en) 2010-12-01
JP2006516622A (ja) 2006-07-06
US20090215825A1 (en) 2009-08-27
JP5260569B2 (ja) 2013-08-14
AU2004210127B2 (en) 2009-10-01
US7572922B2 (en) 2009-08-11
US7989475B2 (en) 2011-08-02
CA2513102C (en) 2011-03-22

Similar Documents

Publication Publication Date Title
ATE490244T1 (de) Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
ATE468853T1 (de) Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
WO2004100875A3 (en) Benzimidazoles, compositions containing such compounds and methods of use
TW200745031A (en) Acyl indoles, compositions containing such compounds and methods of use
WO2004050039A3 (en) Spirocyclic ureas, compositions containing such compounds and methods of use
TW200604179A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
MXPA04000707A (es) Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
DE602004021472D1 (en) Pyrimiidinverbindungen
ATE449604T1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
TW200505903A (en) CGRP receptor antagonists
WO2005013894A3 (en) Benzodiazepine cgrp receptor antagonists
WO2004087649A3 (en) Benodiazepine spirohydantoin cgrp receptor antagonists
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
DE60234616D1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
ATE479655T1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
ATE383345T1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
ATE421519T1 (de) Substituierte bizyklische thiophen-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
EA200601220A1 (ru) Анти-trkc антитела-агонисты и способы их применения
MXPA05012572A (es) Derivado de 5-h-benzo[d]naft[2,1-b]azepina como antagonistas selectivos del receptor d1/d5 para el tratamiento de la obesidad y trastornos del sistema nervioso central.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties